Conference Program November 6-8, 2020
Total Page:16
File Type:pdf, Size:1020Kb
CANO/ACIO 2020 Conference Program November 6-8, 2020 Now and Forever Oncology Nursing World Health Organization The Year of the Nurse and the Midwife Les soins infirmiers en oncologie d’aujourd’hui et de demain Organisation mondiale de la Santé Année des infirmières et des sages-femmes ACCESS MANAGEMENT A FULLY INTEGRATED PROGRAM THAT DELIVERS END-TO-END CARE. At BD, we believe that truly effective vascular access therapy starts long before the first IV is ever inserted. That’s why we designed the BD® Vascular Access Management program: an integrated solution that spans the continuum of vascular access care. The program aims to help clinicians reduce complications and improve quality of care by standardizing on industry best practices throughout the entire process. With the combined expertise of BD and BARD—now as one BD—our program offers in-depth assessments, evidence-based recommendations, training and education, and world-class tools and technologies. Discover total vascular access management designed to deliver better clinical and economic outcomes. Discover the new BD. Learn more at bd.com/TotalManagement BD and the BD Logo are trademarks of Becton, Dickinson and Company or its affiliates. © 2019 BD. All rights reserved. BD-9535 (0419) The image depicted contains models and is being used for illustrative purposes only. Janssen Global Services, LLC. © JGS 2019 Some treatments manage cancer. We’re out to cure it. Our biggest goal is to stop cancer before it can adapt and evolve. That’s why we’re developing innovative personalized therapies, and other treatments to harness the body’s natural defenses. Everything we do gets us closer to a future where disease is a thing of the past. Learn more at www.janssen.com/canada. Janssen Inc. 19 Green Belt Drive | Toronto, Ontario | M3C 1L9 | www.janssen.com/canada © 2020 Janssen Inc. | All trademarks used under license. | vx200007 vx200007_13-02_JAN-ONC-Ad_PNT_8.5x11_CA_EN.indd 1 2020-10-20 3:59 PM NOW REIMBURSED in most provinces (criteria apply)* Visit venclextareimbursement.ca CONFRONT R/R CLL WITH to find out more! PrVENCLEXTA® + RITUXIMAB1 In an open-label study, VENCLEXTA + rituximab demonstrated superior PFS compared with bendamustine + rituximab1† • 81% reduction in instantaneous risk of progression or death vs. bendamustine + rituximab (HR: 0.19 [95% CI: 0.13‑0.28]; p<0.0001).1 • The 2‑year rates of PFS for the VENCLEXTA + rituximab and bendamustine + rituximab arms were 82.76% (95% CI: 76.62‑88.90) and 39.42% (95% CI: 31.03‑47.82), NCCN Guidelines‡ Category 1 recommendation: respectively (IRC‑assessed in the ITT Venetoclax + rituximab is recommended as a preferred regimen for R/R CLL3 population).1,2 Indication and clinical use: • Neutropenia; dose interruption/reduction For more information: VENCLEXTA (venetoclax) in combination with rituximab recommended for severe neutropenia; prophylactic use Please consult the Product Monograph at is indicated for the treatment of adult patients with CLL who of growth factors (e.g. G-CSF) may be considered. abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/ have received at least one prior therapy. • Immunization using live vaccines should be avoided products/VENCLEXTA_PM_EN.pdf for important information No safety and efficacy data for VENCLEXTA in children during treatment and thereafter until B-cell recovery. relating to adverse reactions, drug interactions and dosing and adolescents below 18 years of age are available. • Monitor for signs of infection and have their complete information which have not been discussed in this piece. blood counts monitored throughout treatment. The Product Monograph is also available by calling Contraindication: • Recommended dose not determined for patients 1-888-704-8271 or 514-906-9771. Concomitant use with strong CYP3A inhibitors at initiation with severe renal impairment (CrCl <30 mL/min) or * VENCLEXTA is currently listed as an exception benefit on the formulary of and during ramp-up phase. the following provinces: Alberta (Outpatient Cancer Drug Benefit Program), on dialysis. British Columbia (BC Cancer – Compassionate Access Program), Manitoba • Females of reproductive potential: test to exclude (Cancer Care Manitoba), New Brunswick (New Brunswick Prescription Drug Most serious warnings and precautions: pregnancy before treatment; use of effective Plan), Nova Scotia (Nova Scotia Formulary Updates), Ontario (Cancer Care • VENCLEXTA should only be prescribed by Ontario), Saskatchewan (Saskatchewan Cancer Agency) and Quebec (Liste contraceptives during treatment and for at least 30 days des médicaments – établissements). a qualified physician who is experienced after last dose. † Based on results from a randomized (1:1), multicentre, open-label, Phase 3 in the use of anti-cancer agents. • Male fertility may be compromised. study that evaluated the efficacy and safety of VENCLEXTA in combination with rituximab versus bendamustine in combination with rituximab in • VENCLEXTA is only available through specialty • Avoid use during pregnancy. pharmacies and/or retail oncology pharmacies patients with relapsed/refractory CLL who had received at least one line • Breastfeeding should be discontinued. of prior therapy. Patients previously treated with VENCLEXTA were excluded. that are part of AbbVie’s managed Patients in the VENCLEXTA + rituximab arm completed the 5-week ramp-up distribution program. • No overall difference in effectiveness and safety observed schedule of VENCLEXTA and received 400 mg VENCLEXTA daily for 24 months • Tumour lysis syndrome (TLS) in patients ≥65 years of age compared to younger from Day 1, Cycle 1 of rituximab in the absence of disease progression or patients. In the combination study (MURANO), patients unacceptable toxicity. After the 5-week dose ramp-up, rituximab was initiated at 375 mg/m2 for Cycle 1 and 500 mg/ m2 for Cycles 2-6. Each cycle was Weekly dosage ramp-up over a period of 5 weeks, ≥65 years of age experienced higher incidences of with blood chemistry monitoring on each dose 28 days. Patients randomized to bendamustine + rituximab received diarrhea, peripheral oedema, dizziness, blood creatinine bendamustine at 70 mg/ m2 on Days 1 and 2 for 6 cycles and rituximab at the ramp-up is required. increased, constipation, pyrexia and fall than those above described dose and schedule. Following completion of the 24-month Patients must receive prophylaxis for TLS, <65 years of age. treatment in the VENCLEXTA + rituximab arm or 6 cycles of bendamustine + including hydration and anti-hyperuricemics rituximab, patients continued to be followed for disease progression and • Patients with hepatic impairment should be monitored overall survival. A total of 389 patients were randomized; 194 to the prior to initiating treatment. more closely for signs of toxicity. VENCLEXTA + rituximab arm and 195 to the bendamustine + rituximab arm. Concomitant use of strong CYP3A inhibitors R/R: relapsed/refractory; CLL: chronic lymphocytic leukemia; at initiation and during ramp-up phase Severe hepatic impairment: A 50% reduction PFS: progression-free survival; HR: hazard ratio; CI: confidence interval; is contraindicated. in VENCLEXTA dose is recommended throughout ITT: intention-to-treat; IRC: independent review committee; NCCN: National ‡ the initiation, ramp-up phase and steady state Comprehensive Cancer Network ; G-CSF: granulocyte-colony stimulating • Serious infections that may lead to factor; CrCl: creatinine clearance. once daily dose. hospitalization or death. References: 1. VENCLEXTA Product Monograph. AbbVie Corporation. • Monitoring and laboratory tests: tumour burden April 27, 2020. 2. 2-year PFS estimate data. Data on File. AbbVie Corporation. Other relevant warnings and precautions: 3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines‡). Chronic assessment; blood chemistry monitoring; signs Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 4.2020. • Second primary malignancies: monitor patients of infection; complete blood counts; baseline renal December 20, 2019. for the appearance of non-melanoma skin cancers. function and hepatic status. ‡ All other trademarks are the property of their respective owner(s). abbvie.ca 1-888-703-3006 Printed in Canada © AbbVie Corporation VEN/156A – August 2020 VEN20110_VEN156A_Venclexta_CurrentOnc_JAd_8.5x11_E_m1.indd 1 2020-08-26 2:44 PM Place crop marks at -0p9 at marks crop Place Brands. Generics. Biosimilars. Pr TRUXIMA ® is the first Rituxan® (rituximab) biosimilar and has been available to Canadians since 20191,2* Pr Rituximab for Injection 10 mg/mL Intravenous Infusion Biosimilar by design. Biologic by essence. Creative representation of a molecule. Non-Hodgkin’s Lymphoma (NHL)2†‡ Chronic Lymphocytic Leukemia (CLL)2‡ TRUXIMA® (rituximab for injection) is indicated for the TRUXIMA® (rituximab for injection) is indicated for treatment of patients with previously untreated Stage the treatment of patients with previously untreated III/IV follicular, CD20 positive, B-cell non-Hodgkin's or previously treated B-cell chronic lymphocytic lymphoma in combination with CVP (cyclophosphamide, leukemia (B-CLL), Binet Stage B or C, in combination vincristine and prednisolone) chemotherapy. with fludarabine and cyclophosphamide. Pr TRUXIMA®: A proud offering TRUXIMA® has been available from Teva Canada Innovation. in the EU since 2017.3,4* Rituximab for Injection 10 mg/mL Intravenous Infusion For more information: Please consult the Product Monograph at https://www.tevacanada.com/globalassets/ Pr canada-ph2/pdf-documents-en/specialty-pdfs/0620_truxima_pm_en.pdf